Consistently, our real-world data showed that PD-(L)1 inhibitors plus bevacizumab and chemotherapy generated superior PFS rather than OS compared with IC or BC in PD-L1-negative patients, suggesting that bevacizumab might improve the suppressive tumor immune environment (TIME) in this immuno-resistant subpopulation. The gene discussed is CD274; the disease is neoplasm.